Gadolinium contrast agents, used to enhance MRI films, can be extremely dangerous.
Over the past several years it has become apparent that Gadolinium contrast dyes can cause two separate diseases: Gadolinium Deposition Disease (GDD) and Nephrogenic Systemic Fibrosis (NSF).
In December 2017, the FDA announced that it would require a new class warning and additional safety measures addressing Gadolinium retention. In May 2018, manufacturers Bayer, Bracco, GE and Guerbet issued a warning to healthcare providers notifying them of updated Warnings and Precautions on product labels. Labels now warn that Gadolinium can be retained for months or years in several organ systems throughout the body. The warnings go on to state that “consequences of gadolinium retention in the brain have not been established.” The notifications also instruct physicians to provide patients with medication guides detailing the risks of Gadolinium retention prior to receiving a Gadolinium-based contrast agent.
Recently, a unanimous decision from the Sixth Circuit of the U.S. Court of Appeals affirmed a $5 million verdict in favor of an Ohio man who alleged that he and his doctors were not warned that a commonly used MRI contrast dye contained gadolinium—a toxic metal that had the potential to cause a serious and debilitating disease